First Participant Dosed in Study of BPL-003 Neurophysiological Effects
Investigators have dosed the first participant in a new study investigating the neurophysiological effects of BPL-003.
Source: psychiatrictimes.com
📰 Beckley Psytech News
Beckley Psytech News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Beckley Psytech. Real-time updates on events, politics, business and more.
Mood Disorders in the News
The latest in mood disorder news, all in one place.
David Benshoof Klein Beckley Psytech Brian Iacoviello John Kraus Co Ltd Otsuka Pharmaceutical Co Ltd Click Therapeutics Inc
Source: psychiatrictimes.com
atai Life Sciences poised to create value as psychedelic therapies gain traction, analysts believe
Atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has a pipeline of psychedelic and non-psychedelic drug assets that are poised to create value, analysts at...
Beckley Psytech Life Sciences Drug Administration Psychopharmacologic Drugs Advisory Committee On Drugs Advisory Committee Big Pharma
Source: proactiveinvestors.com
Psychiatry Month in Review: March 2024
This March 2024 psychiatry month in review highlights positive phase 2b and phase 2a data for drugs targeting treatment-resistant depression, generalized anxiety disorder, and PTSD.
Beckley Psytech Daniel Karlin Viktoriya Karakcheyeva Emily Bernstein Center At George Washington University Atai Life Sciences
Source: hcplive.com
5-MeO-DMT Study Shows Relief For Treatment-Resistant Depression
5-MeO-DMT used for depression for those who do not respond to traditional and first-line therapeutics; results show a rapid antidepressant response in 55% of patients.
Beckley Psytech Cosmo Feilding Mellen National Institutes Of Health National Institutes 5 Meo Dmt Treatment Resistant Depression
Source: forbes.com
Atai Life Sciences Q4 And Full-Year 2023 Results: Steep Cash Drain Yet 2026 Target Remains, Update On Psychedelic Pipeline - Compass Pathways (NASDAQ:CMPS), ATAI Life Sciences (NASDAQ:ATAI)
Beckley Psytech Atai Life Sciences Hercules Capital Benzinga Cannabis Capital Continued Commitment To Transforming Mental Florian Brand
Source: benzinga.com
BPL-003 Shows Rapid Antidepressant Effect for Treatment-Resistant Depression
A phase 2a open-label study found BL-003 for treatment-resistant depression was well-tolerated and any acute effects resolved on average in less than 2 hours.
Beckley Psytech Atai Life Sciences Life Sciences Depression Rating Depression Rating Scale Florian Brand
Source: hcplive.com
Atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights
Strategic investment in Beckley Psytech to accelerate the development of psychedelic-based therapies that fit within the two hour in-clinic treatment paradigm established by Spravato®Initial BPL-003 ...
United States Beckley Psytech Exchange Commission Schizophrenia International Research Demerx Ib Inc Hercules Capital Inc
Source: marketscreener.com
atai Life Sciences Reports Fourth Quarter and Full Year
Strategic investment in Beckley Psytech to accelerate the development of psychedelic-based therapies that fit within the two hour in-clinic treatment...
United States Beckley Psytech Life Sciences Securities Exchange Schizophrenia International Research Hercules Capital Inc
Source: globenewswire.com